COIOSDeep risk insights through multi-disciplinary research across the globe
City skyline at dusk with electrical towers
Item refines Peer-reviewed Added

GLP-1 drugs did not reduce new sleep apnoea diagnoses in UK diabetes patients

Among UK adults with type 2 diabetes and obesity, those starting a GLP-1 drug rather than a weight-neutral DPP-4 inhibitor had no fewer new sleep apnoea diagnoses (hazard ratio 1.07).

The study compared 47,315 adults starting a GLP-1 receptor agonist with 159,066 starting a DPP-4 inhibitor in UK CPRD records from 2007 to 2023. All had type 2 diabetes, a BMI of at least 30 and no prior sleep apnoea. New sleep apnoea was diagnosed at 5.8 per 1,000 person-years on GLP-1 drugs and 5.4 on DPP-4 inhibitors.

Why it is interesting: Trials show reduced apnoea severity; in routine care, GLP-1 drugs brought no fewer new diagnoses.

Source
American Journal of Respiratory and Critical Care Medicine, 15 September 2026
Paper
Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study
Authors
Khouri C, Dell'Aniello S, Jambon Barbara C, Azoulay L, Suissa S, Pepin JL
DOI
10.1093/ajrccm/aamag474
Type
Peer-reviewed article
Design
Active-comparator, new-user cohort study in UK CPRD, 2007-2023; 47,315 GLP-1 RA vs 159,066 DPP-4 inhibitor initiators with type 2 diabetes and BMI =30, up to 3 years' follow-up
Verdict
Refines prior evidence
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today